1. Academic Validation
  2. Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22

Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22

  • bioRxiv. 2025 Aug 30:2025.08.29.673087. doi: 10.1101/2025.08.29.673087.
Kevin C Robertson 1 2 Sascha J Amann 3 4 Tongkun Liu 5 Adam V Funk 5 Xianxi Wang 1 2 Irina Grishkovskaya 3 John R Tabor 5 Jacqueline L Norris-Drouin 5 Cheryl H Arrowsmith 6 Jon L Collins 7 Michael J Emanuele 1 2 David Haselbach 3 Lindsey I James 2 5 Nicholas G Brown 1 2
Affiliations

Affiliations

  • 1 Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • 2 Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
  • 3 Research Institute of Molecular Pathology (IMP), ViennaBioCenter (VBC), Campus-Vienna-Biocenter 1, 1030, Vienna, Austria.
  • 4 Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, 1030, Vienna, Austria.
  • 5 Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • 6 Structural Genomics Consortium, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • 7 Office of the Vice Chancellor for Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract

Targeted protein degradation (TPD) through the ubiquitin-proteasome system is driven by compound-mediated polyubiquitination of a protein-of-interest by an E3 ubiquitin (Ub) Ligase. To date, relatively few E3s have been successfully utilized for TPD and the governing principles of functional ternary complex formation between the E3, degrader, and protein target remain elusive. FBXO22 has recently been harnessed by several groups to target different proteins for degradation. FBXO22 recruitment has been enabled through degraders that covalently modify its cysteine residues. Here, we reveal that the aldehyde derivative of UNC10088 promotes cooperative binding of FBXO22 to NSD2, a Histone Methyltransferase and oncogenic protein, leading to a cryo-EM structure of the full SKP1-CUL1-F-box (SCF)-FBXO22 complex with NSD2. This structure revealed a conformational change in the FBXO22 loop surrounding C326, further exposing the cysteine for covalent recruitment. Additional medicinal chemistry efforts led to the discovery of benzaldehyde-based non-prodrug degraders that similarly engage C326 of FBXO22 and potently degrade NSD2. Furthermore, unlike many degraders, our molecules recruit NSD2 to a different surface of FBXO22 than the known FBXO22 substrate BACH1, allowing for concurrent complex formation and degradation of both the neosubstrate and endogenous substrates. Overall, we demonstrate the biochemical and structural basis for NSD2 degradation, revealing key principles for efficient and selective TPD by SCFFBXO22.

Keywords

Nuclear receptor-binding SET domain-containing 2 (NSD2); SKP1–CUL1–F-box (SCF); Targeted protein degradation; Ubiquitin Ligase; cullin-RING ligase.

Figures
Products